TickerFacts.

Ocugen, Inc. (OCGN): Revenue

Annual figures by period end, from SEC filings.

$4.41M
Year ended 2025-12-31
$4.58M
Trailing 12 months to 2026-06-30
+21.0%
3-year compound annual growth
$6.04M2014-12-31: $02015-12-31: $02016-12-31: $02017-12-31: $02018-12-31: $02022-12-31: $2.49M2023-12-31: $6.04M2024-12-31: $4.05M2025-12-31: $4.41M$4.41M
2014-12-31 Revenue (USD) 2025-12-31
Period endedRevenueChange YoYSource filing
2025-12-31$4.41M+8.8%2026-03-04, From 2025-01-01
2024-12-31$4.05M-32.8%2026-03-04, From 2024-01-01
2023-12-31$6.04M+142.6%2025-03-05, From 2023-01-01
2022-12-31$2.49Mn/a2024-04-16, From 2022-01-01
No annual figure between 2018-12-31 and 2022-12-31.
2018-12-31$0n/a2019-03-22, From 2018-01-01
2017-12-31$0n/a2019-03-22, From 2017-01-01
2016-12-31$0n/a2018-03-15, From 2016-01-01
2015-12-31$0n/a2017-03-16, From 2015-01-01
2014-12-31$0n/a2016-03-10, From 2014-01-01

Revenue at similar companies

Companies with the same SEC industry code (Biological Products, (No Diagnostic Substances)), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedRevenueChange YoY
Ocugen, Inc. (OCGN)2025-12-31$4.41M+8.8%
Prime Medicine, Inc. (PRME)2025-12-31$4.63M+55.3%
CG Oncology, Inc. (CGON)2025-12-31$4.04M+254.7%
Zeo ScientifiX, Inc. (ZEOX)2025-10-31$5.20M+12.5%
CRISPR Therapeutics AG (CRSP)2025-12-31$3.51M-90.6%
Surrozen, Inc. (SRZN)2025-12-31$3.48M-67.4%
DBV Technologies S.A. (DBVT)2025-12-31$5.64M+35.8%
Dyadic International Inc (DYAI)2025-12-31$3.09M-11.6%
Fate Therapeutics Inc (FATE)2025-12-31$6.65M-51.2%

Compare OCGN, PRME, CGON, ZEOX side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗